selected publications
- SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular cancer therapeutics. 2020 Academic Article GET IT
-
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
Nature communications.
2019
Academic Article
GET IT
Times cited: 141 -
Treatment resistance in urothelial carcinoma: an evolutionary perspective.
Nature reviews. Clinical oncology.
2018
Information Resource
GET IT
Times cited: 18 -
A critical review on ramucirumab in the treatment of advanced urothelial cancer.
Future oncology (London, England).
2017
Information Resource
GET IT
Times cited: 4 -
Emerging Variants of Castration-Resistant Prostate Cancer.
Current oncology reports.
2017
Information Resource
GET IT
Times cited: 142 -
PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017
Editorial Article
GET IT
Times cited: 3 - Trimodality therapy in variant urothelial carcinoma: choose wisely. Translational andrology and urology. 2017 Editorial Article GET IT
-
Antibody therapeutics for treating prostate cancer: where are we now and what comes next?.
Expert opinion on biological therapy.
2016
Information Resource
GET IT
Times cited: 3 - Dual light chain extramedullary myeloma presenting with mediastinal lymphadenopathy and lytic bone lesions. 2016 GET IT
-
Designing a broad-spectrum integrative approach for cancer prevention and treatment.
Seminars in cancer biology.
2015
Information Resource
GET IT
Times cited: 259 -
Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives.
World journal of gastrointestinal oncology.
2015
Review
GET IT
Times cited: 33 - GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015 Letter GET IT
-
Acute renal infarction associated with homozygous methylenetetrahydrofolate reductase mutation C677T and IgA beta-2-glycoprotein antibodies.
2015
GET IT
Times cited: 6 -
Feasibility of energy medicine in a community teaching hospital: an exploratory case series.
Journal of alternative and complementary medicine (New York, N.Y.).
2015
Academic Article
GET IT
Times cited: 2 -
Composite angioimmunoblastic T-cell and diffuse large B-cell lymphoma.
2015
GET IT
Times cited: 2 -
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.
Seminars in cancer biology.
2015
Review
GET IT
Times cited: 540 -
Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.
Frontiers in oncology.
2015
Review
GET IT
Times cited: 54 - Saddle pulmonary embolism as the initial manifestation of pancreatic cancer. 2015 GET IT
-
Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
Cancer biomarkers : section A of Disease markers.
2015
Academic Article
GET IT
Times cited: 37 - Angiomyolipomas, renal cell carcinomas and pulmonary lymphangioleiomyomatosis. Journal of clinical and diagnostic research : JCDR. 2014 Academic Article GET IT
- Bevacizumab in advanced cervical cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2014 Letter GET IT
- Common hepatic duct stricture: are lithiasis and negative brush cytology enough to rule out Klatskin tumor? 2014 GET IT
-
Bone metastases and hypercalcaemia from cutaneous squamous cell carcinoma.
2014
GET IT
Times cited: 2 - Efficacy of zibotentan in colorectal cancer--letter. Molecular cancer therapeutics. 2014 Letter GET IT
-
The shaping of invasive glioma phenotype by the ubiquitin-proteasome system.
Cell communication & adhesion.
2013
Review
GET IT
Times cited: 3 -
Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis.
Archives of medical science : AMS.
2013
Academic Article
GET IT
Times cited: 14 -
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma.
Cell biology and toxicology.
2013
Review
GET IT
Times cited: 9 -
The role of ubiquitin-proteasome system in glioma survival and growth.
Growth factors (Chur, Switzerland).
2013
Review
GET IT
Times cited: 8 -
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.
Investigational new drugs.
2013
Academic Article
GET IT
Times cited: 29 -
MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53.
Neurological research.
2013
Academic Article
GET IT
Times cited: 14 -
The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?.
Journal of cell communication and signaling.
2013
Academic Article
GET IT
Times cited: 15 -
Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
2013
Academic Article
GET IT
Times cited: 9 -
Bortezomib downregulates MGMT expression in T98G glioblastoma cells.
Cellular and molecular neurobiology.
2013
Academic Article
GET IT
Times cited: 19 - Hashimoto's Thyroiditis and Kikuchi's Disease: Presentation of a Case and Review of the Literature. Case reports in otolaryngology. 2012 Academic Article GET IT
-
The ubiquitin-proteasome system in glioma cell cycle control.
Cell division.
2012
Academic Article
GET IT
Times cited: 22 -
Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells.
Cancer cell international.
2012
Academic Article
GET IT
Times cited: 5 - Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy. Prostate cancer. 2012 Academic Article GET IT
-
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer.
Lung cancer (Amsterdam, Netherlands).
2012
Academic Article
GET IT
Times cited: 47 -
The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer.
Biomolecules.
2012
Academic Article
GET IT
Times cited: 7 -
Selecting for predisposition to cancer cachexia.
EMBO molecular medicine.
2012
Comment
GET IT
Times cited: 1 - Basic Concepts in Metastatic Cardiac Disease. Cardiology research. 2012 Review GET IT
-
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
International journal of urology : official journal of the Japanese Urological Association.
2012
Academic Article
GET IT
Times cited: 12 -
CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
Urologia internationalis.
2012
Academic Article
GET IT
Times cited: 12 -
Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer.
Journal of negative results in biomedicine.
2012
Academic Article
GET IT
Times cited: 10 - Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?. World journal of experimental medicine. 2011 Review GET IT
-
Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis.
Nutrition and cancer.
2011
Academic Article
GET IT
Times cited: 17 - Pulmonary and cutaneous nodules in an immunocompromised patient. 2011 GET IT
-
Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients.
Oncology.
2011
Academic Article
GET IT
Times cited: 21 -
Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.
Journal of molecular medicine (Berlin, Germany).
2011
Academic Article
GET IT
Times cited: 113 -
Evidence of association between methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a candidate-gene association study in a South-eastern European population.
DNA and cell biology.
2011
Academic Article
GET IT
Times cited: 21 -
p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.
Pathology oncology research : POR.
2011
Academic Article
GET IT
Times cited: 5 -
Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis.
Lung cancer (Amsterdam, Netherlands).
2011
Academic Article
GET IT
Times cited: 56 -
Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells.
Cancer cell international.
2011
Academic Article
GET IT
Times cited: 14 -
Nonbacterial thrombotic (marantic) endocarditis in a patient with colorectal cancer.
2010
GET IT
Times cited: 10 -
AFP-producing hepatoid adenocarcinoma of the stomach: a case report.
Cases journal.
2009
Academic Article
GET IT
Times cited: 8 - Orbital metastasis of breast carcinoma. 2009 GET IT
-
The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation.
Journal of cellular and molecular medicine.
2009
Review
GET IT
Times cited: 26 -
The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation.
Journal of cellular and molecular medicine.
2009
Review
GET IT
Times cited: 14